#USA #New York #Class Action #Levi & Korsinsky #Baxter International

Investors Take Note: Baxter International's Class Action Lawsuit Overview

On November 7, 2025, Levi & Korsinsky, LLP announced a significant development for investors in Baxter International, Inc. (NYSE: BAX). A class action securities lawsuit has been initiated, prompting affected shareholders to act swiftly. The deadline to engage with the firm is set for December 15, 2025.

Background of the Lawsuit

The class action aims to recover losses incurred by investors who were impacted by alleged securities fraud that transpired between February 23, 2022, and July 30, 2025. This lawsuit brings attention to various issues surrounding Baxter’s recently launched product, the Novum LVP (Large Volume Pump).

Key Allegations

The complaint outlines severe claims against Baxter, alleging that the company made misleading statements and concealed critical information regarding the safety and efficacy of the Novum LVP. Specifically, several key deficiencies were highlighted:

1. Systemic Defects: The Novum LVP reportedly experienced systemic defects leading to significant malfunctions, including underinfusion, overinfusion, and the inability to deliver fluids. These malfunctions posed substantial risks to patient safety, potentially resulting in serious injury or death.

2. Neglected Reporting: Baxter was allegedly notified of numerous incidents related to device failures. Furthermore, despite being aware of these risks, the company's responses, such as customer alerts, were deemed inadequate to rectify the underlying problems.

3. Erosion of Trust: As Baxter struggled to address these issues, it became clear that the company's previous reassurances regarding the safety, effectiveness, and market potential of its pumps were misleading. The implications could involve the temporary suspension of all new sales of the Novum LVP, severely impacting customer trust and market performance.

Next Steps for Affected Investors

If you suffered a monetary loss in Baxter International, Inc. during the specified timeframe, it is crucial to consider your options. Investors are encouraged to submit their requests for appointment as lead plaintiffs to the court by the upcoming December 15, 2025, deadline. Importantly, participation in seeking recovery does not require being named as a lead plaintiff.

No Financial Risk

For those identified as class members, participating in the lawsuit comes at no financial cost. Investors can potentially receive compensation without any obligation or out-of-pocket fees, making this a risk-free opportunity to seek restitution.

Why Levi & Korsinsky?

For over 20 years, Levi & Korsinsky has earned a reputation for successfully representing shareholders in high-stakes securities litigation. The firm has secured hundreds of millions in recovery for investors and consistently ranks among the top securities litigation firms in the U.S., as recognized in ISS Securities Class Action Services' Top 50 Report for seven consecutive years.

Contact Information

For more details or to discuss your situation, contact:

• - Levi & Korsinsky, LLP
• - Joseph E. Levi, Esq., Ed Korsinsky, Esq.
• - 33 Whitehall Street, 17th Floor, New York, NY 10004
• - Email: [email protected]
• - Telephone: (212) 363-7500

Baxter International, Inc. investors are encouraged to reach out to understand their rights and options as the litigation progresses. Proper action may lead to valuable compensation for those affected by the alleged securities fraud.